-

Profound Medical Standardizes on AcuityMD Intelligence Platform for MedTech as Foundation for Growing Organization

AcuityMD platform helps drive the first incision-free, radiation-free robotic treatment for prostate disease faster to more healthcare providers nationwide

BOSTON--(BUSINESS WIRE)--AcuityMD, the intelligence platform for the medical technology (MedTech) industry, has been selected by Profound Medical, a medical device company developing customizable, incision-free therapies that combine real-time magnetic resonance imaging, thermal ultrasound, and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue – specifically for prostate diseases. Profound Medical is standardizing its organization on AcuityMD’s complete suite of commercial intelligence solutions to bring its breakthrough TULSA-PRO® technology to more healthcare providers nationwide.

Nearly 60% of men diagnosed with low-risk prostate cancer are managed with active surveillance – a ‘wait-and-see’ approach – because traditional treatments often cause severe, permanent side effects such as incontinence and erectile dysfunction. Profound Medical provides patients with a better alternative for whole or partial gland ablation, whether for low-risk, intermediate-risk, or more severe disease states. Indicated for transurethral ultrasound ablation (TULSA) of prostate tissue, TULSA-PRO is the first incision-free, radiation-free treatment for prostate disease. The procedure, which is now reimbursed by Medicare with a Category 1 CPT code, can also be conveniently performed in various outpatient settings – hospitals, ambulatory surgery centers, and office-based laboratories (OBLs).

AcuityMD provided Profound Medical a smart, efficient way to accelerate the delivery of TULSA-PRO to healthcare providers.

Profound Medical had been using a general customer relationship management (CRM) system with spotty market data. As a fast-growing company, they needed a powerhouse system with integrated MedTech workflows that not only helped sales identify the providers that could benefit from TULSA-PRO but also incorporated reliable commercial intelligence to guide strategic decision-making. Profound Medical also wanted industry-specific functionality for territory, contract, and long-term customer engagement management. After reviewing AcuityMD’s platform – including all modules Pipeline, Targeting, Markets, Territories, plus newer modules Contracts and Care Journeys, both launched in 2024 – and speaking to customer referrals, Profound Medical doubled-down on AcuityMD’s entire suite.

“We are building something important and want to do it right alongside a technology provider that will partner with us as we grow,” said Tom Tamberrino, Chief Commercial Officer at Profound Medical. “The people at AcuityMD are as driven to get TULSA-PRO into the market as we are, and their platform is proving instrumental to helping us identify which physicians are treating prostate disease and where, as well as uncovering the high-volume regions where we need to strategically hire more sales professionals.”

Tamberrino added, “We wanted a solution that was more than a one-note sales tool or generic CRM. AcuityMD provides value not just for our sales professionals but also our regional leaders, financial team, marketers, and even manufacturing groups. It’s a comprehensive platform solution that delivers industry intelligence that all our teams can use for better decision-making.”

AcuityMD’s platform is built for the MedTech industry’s unique commercialization process and combines streamlined workflows with robust data, enabling sales, marketing, and national accounts teams to build comprehensive strategies focused on their best opportunities.

“Profound Medical is solving a longstanding men’s health problem by offering an innovative procedure for prostate disease that also preserves quality-of-life,” said Michael Monovoukas, CEO and co-founder of AcuityMD. “We are proud to partner with Profound Medical to help identify their best opportunities so they can achieve their goals and bring revolutionary TULSA-PRO technology to as many patients as possible.”

About AcuityMD

AcuityMD is the intelligence platform for MedTech. More than 300 MedTech companies – including six of the top 10 – use AcuityMD to identify target markets, surface top opportunities, and grow their business. With customers ranging from pre-commercial to enterprise, AcuityMD is committed to delivering the right insights so companies can understand where and how to sell faster to accelerate the adoption of medical technology.

Contacts

Media Contact:
Lisa Barbadora, Barbadora INK for AcuityMD
+1 (610) 420-3413
lbarbadora@barbadoraink.com

AcuityMD


Release Versions

Contacts

Media Contact:
Lisa Barbadora, Barbadora INK for AcuityMD
+1 (610) 420-3413
lbarbadora@barbadoraink.com

Social Media Profiles
More News From AcuityMD

AcuityMD Launches Research Agent in AcuityAI to Take MedTech Market Analysis from Weeks to Minutes

BOSTON--(BUSINESS WIRE)--AcuityMD, the AI platform for MedTech, today introduced advanced market analysis in AcuityAI, powered by a new research agent that delivers company, brand, and product-level market share, pricing comparisons, and patient pathway analyses to calculate total addressable market size in minutes. MedTech leaders gain fast, accurate market analysis – a traditionally time-consuming process – to improve long-term decision-making.MedTech market analysis typically requires piecing...

AcuityMD Brings Prescription Data Into AcuityAI, Helping MedTech Reps Find New Patients Through Healthcare Professionals (HCPs)

BOSTON--(BUSINESS WIRE)--AcuityMD, the AI platform for MedTech, today announced the availability of prescription data in AcuityAI, combining prescription and procedure data in a single workflow for commercial teams. Sales reps can use AcuityAI to find and prioritize healthcare professionals (HCPs) treating patients with prescription (branded and generic) therapies that align with their targets. For many medical device (MedTech) companies, reviewing procedure data reveals only part of the pictur...

AcuityMD Ranked No. 316 on the 2026 Inc. 5000 List, The Most Prestigious Ranking of America’s Fastest-Growing Private Companies

BOSTON--(BUSINESS WIRE)--AcuityMD, the AI platform for MedTech, today announced it has been named to the 2026 Inc. 5000 list of the fastest-growing private companies in America. AcuityMD ranked No. 316, driven by 1,061% three-year revenue growth – roughly 10 times the median revenue growth rate of 130% among 2026 Inc. 5000 honorees. The company also ranked No. 28 out of 362 software companies on the list. This marks AcuityMD’s first appearance on Inc. Magazine’s prestigious annual ranking. The...
Back to Newsroom